Traders Buy High Volume of X4 Pharmaceuticals Call Options (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) was the recipient of some unusual options trading on Tuesday. Stock investors bought 9,665 call options on the company. This represents an increase of approximately 3,751% compared to the average volume of 251 call options.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on XFOR shares. Stifel Nicolaus lowered their price target on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. HC Wainwright reduced their price objective on X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a research note on Thursday, November 14th.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CEO Paula Ragan sold 239,436 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the sale, the chief executive officer now owns 1,057,713 shares of the company’s stock, valued at $581,742.15. The trade was a 18.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Mary Dibiase sold 67,695 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.57, for a total value of $38,586.15. Following the completion of the sale, the chief operating officer now directly owns 452,060 shares of the company’s stock, valued at $257,674.20. This represents a 13.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 580,800 shares of company stock worth $321,447 over the last 90 days. 1.62% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its holdings in X4 Pharmaceuticals by 46.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock worth $55,000 after acquiring an additional 12,514 shares in the last quarter. Verition Fund Management LLC bought a new stake in X4 Pharmaceuticals during the third quarter worth about $30,000. SG Americas Securities LLC bought a new stake in X4 Pharmaceuticals during the third quarter worth about $37,000. XTX Topco Ltd bought a new stake in X4 Pharmaceuticals during the second quarter worth about $65,000. Finally, Rhumbline Advisers raised its holdings in X4 Pharmaceuticals by 14.6% during the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after acquiring an additional 23,831 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Trading Up 1.1 %

Shares of NASDAQ XFOR traded up $0.01 during midday trading on Tuesday, hitting $0.53. The stock had a trading volume of 3,939,884 shares, compared to its average volume of 2,350,655. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. X4 Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $1.60. The company’s 50-day simple moving average is $0.48 and its 200 day simple moving average is $0.67. The firm has a market cap of $91.04 million, a P/E ratio of -5.86 and a beta of 0.35.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.